Pharmaust Stock

Pharmaust ROCE 2024

Pharmaust ROCE

-0.57

Ticker

PAA.AX

ISIN

AU000000PAA1

WKN

A0DNJ3

In 2024, Pharmaust's return on capital employed (ROCE) was -0.57, a 174.28% increase from the -0.21 ROCE in the previous year.

Pharmaust Aktienanalyse

What does Pharmaust do?

Pharmaust Ltd is a biotechnology company based in Perth, Australia. The company was founded in 2001 by Dr. Roger Aston and Dr. Paul Gavin as a spin-off from the School of Biomedical Sciences at Curtin University of Technology. Their goal was to advance the discovery and development of novel therapeutics and diagnostics for cancer and autoimmune diseases. Pharmaust's history began with the discovery of a novel molecule called PPL-1 by Dr. Roger Aston. This molecule had the potential to serve as a cancer therapeutic as it could inhibit the release of tumor cells. Pharmaust researchers held patents for PPL-1 in the US, Europe, and Australia. Another important milestone for Pharmaust was the discovery of a new class of compounds with potential cancer and autoimmune therapeutics known as PPL-100, PPL-300, and PPL-400. Pharmaust's business model is focused on bringing novel drugs and diagnostics to market and selling them. Pharmaust aims to use its technologies to reduce the high costs of drug research and ultimately help patients suffering from serious diseases. Pharmaust has several divisions, including: - Pharmaceutical research and development: Pharmaust is working to discover and develop new therapeutics and diagnostics, particularly for the treatment of cancer and autoimmune diseases. - Clinical research: Pharmaust conducts clinical trials to assess the safety and efficacy of its drugs and obtain the necessary approvals for market authorization. - Licensing and marketing: Pharmaust markets its products in Australia and other countries, and licenses its technologies to other biopharmaceutical companies to generate additional revenue. Pharmaust's current product portfolio includes two main products sold under the brand names Monepantel and PPL-003. Monepantel is an anthelmintic used to treat parasite infestation in livestock such as sheep and goats. PPL-003 is an immunotherapy for the treatment of skin cancer, currently being tested in clinical trials. In particular, Pharmaust has developed a therapy in recent years that supports immunotherapy and works closely with clinics and payers to further develop and market their therapy. Pharmaust has received numerous awards and recognitions in recent years, including the award for Perth's Best Emerging Company and recognition from the Western Australian Industry and Export Awards (WAIEA) and the Australasian Society for Stem Cell Research (ASSCR). In conclusion, Pharmaust Ltd remains committed to saving and improving lives. The company sees a promising future in the discovery, development, and marketing of novel therapeutics and diagnostics for the treatment of serious diseases. By integrating four different drug classes, Pharmaust is working on a range of early-stage development projects that have the potential to help patients suffering from various diseases. Pharmaust ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Pharmaust's Return on Capital Employed (ROCE)

Pharmaust's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Pharmaust's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Pharmaust's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Pharmaust’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Pharmaust stock

What is the ROCE (Return on Capital Employed) of Pharmaust this year?

The ROCE of Pharmaust is -0.57 undefined this year.

How has the ROCE (Return on Capital Employed) of Pharmaust developed compared to the previous year?

The ROCE of Pharmaust has increased by 174.28% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Pharmaust?

A high Return on Capital Employed (ROCE) indicates that Pharmaust has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Pharmaust?

A low ROCE (Return on Capital Employed) can indicate that Pharmaust has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Pharmaust impact the company?

An increase in the ROCE of Pharmaust can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Pharmaust affect the company?

A decrease in ROCE of Pharmaust can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Pharmaust?

Some factors that can affect Pharmaust's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Pharmaust so important for investors?

The ROCE of Pharmaust is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Pharmaust take to improve the ROCE?

To improve the ROCE, Pharmaust can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Pharmaust pay?

Over the past 12 months, Pharmaust paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pharmaust is expected to pay a dividend of 0 AUD.

What is the dividend yield of Pharmaust?

The current dividend yield of Pharmaust is .

When does Pharmaust pay dividends?

Pharmaust pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pharmaust?

Pharmaust paid dividends every year for the past 0 years.

What is the dividend of Pharmaust?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pharmaust located?

Pharmaust is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pharmaust kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pharmaust from 10/24/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 10/24/2024.

When did Pharmaust pay the last dividend?

The last dividend was paid out on 10/24/2024.

What was the dividend of Pharmaust in the year 2023?

In the year 2023, Pharmaust distributed 0 AUD as dividends.

In which currency does Pharmaust pay out the dividend?

The dividends of Pharmaust are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Pharmaust

Our stock analysis for Pharmaust Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharmaust Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.